The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

Also Read: Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say The collaboration focuses on discovering and developing RNA-editing ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

In its lawsuit against several healthcare giants, the county contends insulin costs jumped more than 1,000 percent, with medications that cost manufacturers approximately $2 per vial to produce ...

Bucks County has joined municipalities across the nation in suing major insulin manufacturers and drug price negotiating ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index, which ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from US rival Eli Lilly, makes inroads into its market share and as its pipeline of new ...